Clinical trials
Castration Resistant Prostatic Cancer clinical trials
Below are recruiting castration resistant prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 291 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT06585007RecruitingPhase 3
Radiation for limited cancer growth in castration-resistant prostate cancer
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
LeuvenAges 18 years+ - NCT07751133RecruitingPhase 3
Hormone therapy dosing study for metastatic prostate cancer
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
ManchesterAges 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Coral Springs, FloridaAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT07698535RecruitingPhase 2
Blood test to guide early stopping of prostate cancer therapy
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Seattle, WashingtonAges 18 years+ - NCT07691697Recruiting
Targeted radiation for limited prostate cancer spread
This trial tests whether giving focused radiation to a small number of growing prostate cancer spots can help control the disease while you continue your current systemic treatment. It may delay the need to switch treatments and is for people whose cancer has spread to only a few places.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07621692RecruitingPhase 1
New radioactive therapy for advanced prostate cancer
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
TaipeiAges 20 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Duarte, CaliforniaAges 18–99 - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT06720532Recruiting
Kidney function in men with prostate cancer getting a new targeted radiation therapy
This study looks at how a targeted radiation therapy called 177Lu-PSMA affects kidney function in men with a type of advanced prostate cancer. It aims to understand risk factors to help guide safe treatment.
MunichAges 18 years+ - NCT04104607RecruitingPhase 1
Testing a PSMA-targeted immune drug for advanced prostate cancer
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07581184RecruitingPhase 1
Targeted Radioactive Therapy for Advanced Prostate Cancer
This Phase 1 trial tests a new radioactive treatment called [225Ac]Ac-AKY-2519 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug carries radioactivity directly to cancer cells to try to shrink tumors and slow disease progression.
Irvine, CaliforniaAges 18 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07570979RecruitingPhase 1
Testing INR731 for Metastatic Prostate Cancer
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Boston, MassachusettsAges 18 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07549256RecruitingPhase 2
Cannabidiol for pain relief in advanced prostate cancer
This trial tests a cannabis-derived medicine called cannabidiol (CBD) for pain relief in men with advanced prostate cancer that has stopped responding to standard treatments. The goal is to see if CBD can help reduce pain when other options have been exhausted.
GistrupAges Any age
Hear when a new Castration Resistant Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castration resistant prostatic cancer?
- Yes. Clin2 currently lists 291 recruiting castration resistant prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castration resistant prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castration resistant prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Prostatic Neoplasms, Castration-Resistant
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Platinum-resistant Ovarian Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.